司帕沙星和米诺环素治疗非淋球菌性尿道炎的随机对比研究

为评价司帕沙星对男性非淋球菌性尿道炎的治疗作用，将160例男性非淋球菌性尿道炎患者随机分为两组，每组各80例，分别采用司帕沙星（200mg，每天一次）和米诺环素（100mg，每天2次）治疗，疗程均为14d。结果，司帕沙星组与米诺环素组临床总有效率分别为88．8％、91．3％，对沙眼衣原体性尿道炎有效率分别为93．8％、96．0％，对解脲尿枝原体性尿道炎有效率分别为78．1％、83．3％，以上结果统计学均无显著性差异；药敏试验显示沙眼衣原体对司帕沙星与米诺环素敏感率分别为94．9％、96．9％，解脲尿枝原体对两者敏感率分别为81．9％、87．1％，两组数据统计学无显著差异；两组不良反应发生率分别为6．3％、8．8％，无显著差异（P＞0．05），提示司帕沙星是一个高效、安全的抗菌药物，治疗非淋球菌性尿道炎疗效确切，可作为一线药物。

Randomized controlled study on sparfloxacin and minocycline in treatment of male nongonococcal urethritis

To study the therapeutic effects of sparfloxacin on treating male nongonococcal urethritis. 160 male nongonococcal were randomly divided into two groups. One group ( n =80) was treated with sparflo xacin 200mg. po, qd for 14d, the other group ( n =80)was treated with minocycline 100mg, po, bid for 14d. The total effective rates were 88.8% in sparfloxacin group, and 91.3% in minocycline group, P >0.05. The sensitivity rates of Chlamydia trachomatis to sparfloxacin and minocycline were 94.9% and 96.9%, respec tively , P >0.05. The sensitivity rates of Ureaplasma urealyticum to sparfloxacin and minocyline were 81.8% and 87.1%, respectively, P >0.05. The adverse reaction rates of sparfloxacin and minocycline were 6.3% and 8.8%, respectively, P >0.05. Conclusion: Sparfloxacin is an effective and safe antibiotic in treating male nongococcal urethritis, it may become one of the first line drugs for this disease.